Culmerciclib vs Eciruciclib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: CDK2/CDK4/CDK6 · full HR+/HER2- Metastatic Breast Cancer pipeline

Culmerciclib

Marketed by Sino Biopharmaceutical

Phase 3 in HR+/HER2- Metastatic Breast Cancersmall molecule
Partial signal

NCT05375461 · Phase 3 · completed

This randomized, double-blind, placebo-controlled Phase 3 trial randomized 293 patients with pretreated HR-positive, HER2-negative advanced breast cancer 2:1 to culmerciclib plus fulvestrant or placebo plus fulvestrant. The sample size was planned for 90% power to detect a hazard ratio of 0.60 in investigator-assessed progression-free survival, the primary endpoint, with at least 287 patients needed. At the prespecified interim analysis, median PFS was 16.6 months with culmerciclib and 7.5 months with placebo (HR 0.36, 95% CI 0.26 to 0.51, P < 0.001), so the primary endpoint was met. Overall survival was immature (Signal Transduct Target Ther 2025).

Next expected readout: December 2026 · NCT06202261 (registry estimate)

Reported efficacy

Progression-free survival (PFS) (Baseline up to 24 months): Median investigator-assessed PFS: 16.6 months (culmerciclib + fulvestrant) vs 7.5 months (placebo + fulvestrant); HR 0.36 (95% CI 0.26-0.51), P<0.001, meeting the primary endpoint. (met)

Result source: NCT05375461

Eciruciclib

Developed by Beta Pharma, Inc.

Phase 1/2 in HR+/HER2- Metastatic Breast Cancersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCulmerciclibEciruciclib
PFS, median16.6 vs 7.5a+9.1 vs placeboNCT05375461—Not reported
OS, median—Not posted · NCT05375461—Not reported
ORR—Not posted · NCT05375461—Not reported
Clinical benefit rate—Not posted · NCT05375461—Not reported

PFS, median

Culmerciclib
16.6 vs 7.5a+9.1 vs placeboNCT05375461
Eciruciclib
—Not reported

OS, median

Culmerciclib
—Not posted · NCT05375461
Eciruciclib
—Not reported

ORR

Culmerciclib
—Not posted · NCT05375461
Eciruciclib
—Not reported

Clinical benefit rate

Culmerciclib
—Not posted · NCT05375461
Eciruciclib
—Not reported
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Eciruciclib: no structured comparison results are available for HR+/HER2- Metastatic Breast Cancer.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Culmerciclib

PFS 16.6 vs 7.5 placebo months
time to event · months
NCT05375461 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Culmerciclib's landscape · Eciruciclib's landscape